GlaxoSmithKline and Innoviva Inc. recently reported that patients whose asthma was well-controlled could use Relvar Ellipta once per day, which is less frequent than other treatments.
Those who took part in the test took the Relvar Ellipta 100/25 once a day by mouth and had previously used the Seretide Accuhaler 250/50 twice a day, according to an announcement. Those who took the Relvar Ellipta did not see any worsening in how their lungs operated.
The test was given to show that Relvar Ellipta 100/25 worked just as well as the Seretide Accuhaler 250/50 for adults and teenagers older than 12 who have bronchial asthma that returns.
The scientists tested a third medicine, fluticasone propionate, to contrast how patients' lungs worked between the Relvar Ellipta and the Seretide Accuhaler.
That test came after those who took part in the test used the Seretide Accuhaler 250/50 two times a day for four weeks. Those who had effectively managed their asthma were chosen without any preconceived plan whether they would continue with the Seretide Accuhaler, whether they would get the Relvar Ellipta or whether they would get the fluticasone propionate 250, with both the Accuhaler and fluticasone propionate being taken two times a day.